共 50 条
- [1] PACE: A PIVOTAL PHASE 2 TRIAL OF PONATINIB IN PATIENTS WITH CML AND PH plus ALL RESISTANT OR INTOLERANT TO DASATINIB OR NILOTINIB, OR WITH THE T315I MUTATIONHAEMATOLOGICA, 2012, 97 : 453 - 453Cortes, J.Kim, D. W.Pinilla, J.Paquette, R.Le Coutre, P.Chuah, C.Nicolini, F.Apperley, J.Khoury, J.Talpaz, M.DiPersio, J.D'Angelo, D.Rea, D.Abruzzese, E.Mueller, M.Baccarani, M.Gambacorti-Passerini, C.Christopher, C.Haluska, F.Kantarjian, H.
- [2] Initial Findings From the PACE Trial: A Pivotal Phase 2 Study of Ponatinib in Patients with CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I MutationBLOOD, 2011, 118 (21) : 52 - 53Cortes, Jorge E.Kim, Dong-WookPinilla-Ibarz, JavierLe Coutre, Philipp D.Chuah, CharlesNicolini, Franck E.Paquette, RonApperley, Jane F.DiPersio, John F.Khoury, H. JeanRea, DelphineTalpaz, MosheDeAngelo, Daniel J.Abruzzese, ElisabettaBaccarani, MicheleMueller, Martin C.Gambacorti-Passerini, CarloWong, StephaneLustgarten, StephanieTurner, Christopher D.Rivera, Victor M.Clackson, TimHaluska, FrankKantarjian, Hagop M.
- [3] PONATINIB IN PATIENTS (PTS) WITH PHILADELPHIA CHROMOSOME- POSITIVE (PH plus ) LEUKEMIAS RESISTANT OR INTOLERANT TO DASATINIB OR NILOTINIB, OR WITH THE T315I MUTATION: LONGER-TERM FOLLOW-UP OF THE PACE TRIALHAEMATOLOGICA, 2014, 99 : 334 - 334le Coutre, P. D.Kim, D. W.Pinilla-Ibarz, J.Paquette, R.Chuah, C.Nicolini, F. E.Apperley, J. F.Khoury, H. J.Talpaz, M.DiPersio, J. F.DeAngelo, D.Abruzzese, E.Rea, D.Baccarani, M.Muller, M.Gambacorti-Passerini, C.Lustgarten, S.Haluska, F. G.Guilhot, F.Deininger, M. W.Hochhaus, A.Hughes, T. P.Shah, N. P.Kantarjian, H. M.Cortes, J. E.
- [4] A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE TrialBLOOD, 2012, 120 (21)Cortes, Jorge E.Kim, Dong-WookPinilla-Ibarz, Javierle Coutre, PhilippPaquette, RonChuah, CharlesNicolini, Franck E.Apperley, JaneKhoury, H. JeanTalpaz, MosheDiPersio, John F.DeAngelo, Daniel J.Abruzzese, ElisabettaRea, DelphineBaccarani, MicheleMuller, Martin C.Gambacorti-Passerini, CarloWong, StephaneLustgarten, StephanieRivera, Victor M.Clarkson, TimTurner, Christopher D.Haluska, Frank G.Guilhot, FrancoisDeininger, Michael W.Hochhaus, AndreasHughes, TimothyGoldman, John M.Shah, NeilKantarjian, Hagop M.
- [5] Ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph plus ) leukemias resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation: Longer-term follow up of the PACE trial.JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Kantarjian, Hagop M.Kim, Dong-WookPinilla-Ibaz, JavierLe Coutre, Philipp D.Paquette, RonaldChuah, CharlesNicolini, Franck E.Apperley, JaneKhoury, Hanna JeanTalpaz, MosheDiPersio, John F.Baccarani, MicheleLustgarten, StephanieHaluska, Frank G.Guilhot, FrancoisDeininger, Michael W. N.Hochhaus, AndreasHughes, Timothy P.Shah, Neil P.Cortes, Jorge E.
- [6] Ponatinib In Patients (pts) With Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL) Resistant Or Intolerant To Dasatinib Or Nilotinib, Or With The T315I BCR-ABL Mutation: 2-Year Follow-Up Of The PACE TrialBLOOD, 2013, 122 (21)Cortes, Jorge E.Kim, Dong-WookPinilla-Ibarz, Javierle Coutre, Philipp D.Paquette, RonaldChuah, CharlesNicolini, Franck E.Apperley, Jane F.Khoury, H. JeanTalpaz, MosheDiPersio, John F.DeAngelo, Daniel J.Abruzzese, ElisabettaRea, DelphineBaccarani, MicheleMueller, Martin C.Gambacorti-Passerini, CarloLustgarten, StephanieRivera, Victor M.Clackson, TimTurner, Christopher D.Haluska, Frank G.Guilhot, FrancoisDeininger, Michael W.Hochhaus, AndreasHughes, Timothy P.Goldman, John M.Shah, Neil P.Kantarjian, Hagop M.
- [7] PONATINIB, A NEW DRUG FOR CML PATIENTS HARBORING THE T315I MUTATIONANTICANCER RESEARCH, 2011, 31 (05) : 1966 - 1966Dempke, W. C. M.Rolinski, B.Zippel, R.
- [8] A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph plus CML or relapsed/refractory Ph plus ALLINTERNATIONAL JOURNAL OF HEMATOLOGY, 2009, 89 (05) : 679 - 688Tojo, ArinobuUsuki, KensukeUrabe, AkioMaeda, YasuhiroKobayashi, YukioJinnai, ItsuroOhyashiki, KazumaNishimura, MikiKawaguchi, TatsuyaTanaka, HideoMiyamura, KoichiMiyazaki, YasushiHughes, TimothyBranford, SusanOkamoto, ShinichiroIshikawa, JunOkada, MasayaUsui, NorikoTanii, HiromiAmagasaki, TaroNatori, HirokoNaoe, Tomoki
- [9] Epidemiological Study on Survival of Chronic Myeloid Leukemia (CML) and Ph plus Acute Lymphoblastic Leukemia (ALL) Patients with T315I Mutation. Final AnalysisBLOOD, 2008, 112 (11) : 76 - 77Nicolini, Franck E.Martinelli, GiovanniKim, Dong-WookHochhaus, AndreasMauro, Michael J.Cortes, JorgeChuah, CharlesDufva, IngeApperley, Jane F.Yagasaki, FumiharuPearson, JayPeter, SenakaRodriguez, Cesar SanzGiles, FrankGoldman, John M.Zhou, Wei
- [10] A Phase 1/2 Study to Evaluate the Safety and Efficacy of Ponatinib with Chemotherapy in Pediatric Patients with Relapsed, Resistant, or Intolerant Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL) or Have the T315I MutationCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S271 - S272Gore, LiaLoh, MignonPui, Ching-HonHanley, Michael J.Du, JichangMatloub, YousifHennessy, MeliessaGranier, MurielBiondi, AndreaSilverman, Lewis